Prevention and treatment of osteoporosis.
Because the lifetime risk of fragility fracture for a 50-year-old Caucasian woman is about 40 per cent, a whole-life strategy of osteoporosis prevention is necessary. In childhood, primary prevention of osteoporosis is based on exercise and adequate dietary calcium. In women undergoing menopause, hormone replacement therapy administered for at least ten years remains the preventive treatment of choice, and is associated with a substantial reduction in vertebral and non-vertebral fractures. Intranasal salmon calcitonin and bisphosphonates are effective alternatives, but their effects on fracture rate and their long-term safety require further evaluation. Regarding the prevention of the late bone loss leading to senile osteoporosis, there is now evidence that the reduction of the secondary hyperparathyroidism induced by calcium and vitamin D insufficiencies through the administration of calcium and vitamin D supplements significantly decreases the hip fracture incidence. There is no general consensus about the efficacy of treatment for established osteoporosis with fractures. Fluoride salts have proven their direct stimulating effects on bone formation; dosage must be moderate, and the duration of treatment should be limited to 2-3 years in order not to impair the quality of the new bone. Cyclical therapy with etidronate induces beneficial effects on bone mass in the spine, but its effect on the vertebral fracture rate is not yet established. The new bisphosphonates seem to be promising for the management of osteoporosis. Several other agents such as growth factors, silicon derivatives and strontium salts are in various stages of testing. The new definition of osteoporosis proposed by a WHO study group, no longer based on the fracture but on a low bone mass, is of major interest, because it should make possible to have a more effective therapeutic approach, before the occurrence of an irreversible degree of bone loss.
INSERM Unit 403, Edouard Herriot Hospital, Lyon, France.
M C
MC
Chapuy
P J
PJ
Meunier
D005260:Female; D005544:Forecasting; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control*